More well thought out work can be found at — https://axial.substack.com/
Axial invests and partners in early-stage life sciences companies. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company — info@axialsprawl.com
Who leads Vividion?
Vividion is led by Diego Miralles (CEO) with the founders being Benjamin Cravatt, Phil Baran, and Jin-Quan Yu. Diego is the former president of Adaptive Biotechnologies and a former Johnson & Johnson executive. Benjamin, Phil and Jin-Quan are on faculty at Scripps.
What does Vividion do?
Vividion focuses on discovering targeted protein degradation therapeutics like proteolysis targeting chimeras (PROTAC). The company’s comparable is Arvinas — https://axial.substack.com/p/axial-arvinas Vividion has taken some of the IP from Scripps to build out a proteomics pipeline to discover small molecules that target new E3 ligases as well as other high-value targets.
The idea for Vividion is to discover bifunctional small molecules that engage a target as well as an E3 ligase to selectively degrade the target:
